PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.

Gene rearrangement in the form of an intragenic deletion is the primary mechanism of oncogenic mutation of the epidermal growth factor receptor (EGFR) gene in gliomas. However, the incidence of platelet-derived growth factor receptor-α (PDGFRA) gene rearrangement in these tumors is unknown. We investigated the PDGFRA locus in PDGFRA-amplified gliomas and identified two rearrangements, including the first case of a gene fusion between kinase insert domain receptor (KDR) (VEGFRII) and the PDGFRA gene, and six cases of PDGFRA(Δ8, 9), an intragenic deletion rearrangement. The PDGFRA(Δ8, 9) mutant was common, being present in 40% of the glioblastoma multiformes (GBMs) with PDGFRA amplification. Tumors with these two types of PDGFRA rearrangement displayed histologic features of oligodendroglioma, and the gene products of both rearrangements showed constitutively elevated tyrosine kinase activity and transforming potential that was reversed by PDGFR blockade. These results suggest the possibility that these PDGFRA mutants behave as oncogenes in this subset of gliomas, and that the prevalence of such rearrangements may have been considerably underestimated.

[1]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[2]  C. Brennan,et al.  Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations , 2009, PloS one.

[3]  A. Ashworth,et al.  Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas , 2009, British Journal of Cancer.

[4]  A. Kaye,et al.  The EGFRvIII variant in glioblastoma multiforme , 2009, Journal of Clinical Neuroscience.

[5]  D. Pearson,et al.  Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma , 2009, Oncogene.

[6]  D. Housman,et al.  Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis , 2009, Proceedings of the National Academy of Sciences.

[7]  David T. W. Jones,et al.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.

[8]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[9]  Antony V. Cox,et al.  Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing , 2008, Nature Genetics.

[10]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[11]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[12]  B. Johansson,et al.  The impact of translocations and gene fusions on cancer causation , 2007, Nature Reviews Cancer.

[13]  A. Chinnaiyan,et al.  Evidence of recurrent gene fusions in common epithelial tumors. , 2006, Trends in molecular medicine.

[14]  S. Franceschi,et al.  Correlation Among Pathology, Genotype, and Patient Outcomes in Glioblastoma , 2006, Journal of neuropathology and experimental neurology.

[15]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[16]  M. Capogrossi,et al.  Heterodimerization of FGF-receptor 1 and PDGF-receptor-alpha: a novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells. , 2006, Blood.

[17]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[18]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[19]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[20]  S. Levy,et al.  Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Johansson,et al.  Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer , 2004, Nature Genetics.

[22]  Keara M. Lane,et al.  Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) , 2003, Genes, chromosomes & cancer.

[23]  P. Dirks,et al.  A human brain tumor-derived PDGFR-α deletion mutant is transforming , 2003, Oncogene.

[24]  Yuji Saito,et al.  Receptor Heterodimerization: Essential Mechanism for Platelet-Derived Growth Factor-Induced Epidermal Growth Factor Receptor Transactivation , 2001, Molecular and Cellular Biology.

[25]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.

[26]  M. Backer,et al.  Kinase Insert Domain Receptor (KDR) Extracellular Immunoglobulin-like Domains 4–7 Contain Structural Features That Block Receptor Dimerization and Vascular Endothelial Growth Factor-induced Signaling* , 2001, The Journal of Biological Chemistry.

[27]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[28]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[29]  Martin R. Schneider,et al.  PTK 787 / ZK 222584 , a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases , Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration , 2000 .

[30]  M. Nistér,et al.  Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. , 1998, Cancer research.

[31]  H. Varmus,et al.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. , 1998, Genes & development.

[32]  D. Bigner,et al.  Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). , 1997, The Biochemical journal.

[33]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[34]  C. Wernstedt,et al.  A unique autophosphorylation site in the platelet-derived growth factor alpha receptor from a heterodimeric receptor complex. , 1994, European journal of biochemistry.

[35]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[36]  T. Yoshimoto,et al.  Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin. , 1992, Oncogene.

[37]  C. James,et al.  Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. , 1991, Cancer research.

[38]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.